<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099575</url>
  </required_header>
  <id_info>
    <org_study_id>Atonic PPH in high risk group</org_study_id>
    <nct_id>NCT05099575</nct_id>
  </id_info>
  <brief_title>Protocols for Prevention of PPH During CS in High Risk Group</brief_title>
  <official_title>Different Protocols for Prevention of Atonic Postpartum Hemorrhage During Cesarean Delivery in High Risk Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood&#xD;
      after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable&#xD;
      it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH&#xD;
      corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin&#xD;
      and combinations of these drugs can be used but until now there is no agreement on medication&#xD;
      that can be the most effective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of blood loss</measure>
    <time_frame>1 year</time_frame>
    <description>Decrease amount of blood loss</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Finding the drug most effective with least adverse effects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">448</enrollment>
  <condition>Atonic PPH</condition>
  <arm_group>
    <arm_group_label>Pregnant women who receive oxytocin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant Women who receive carbetocin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women who receive misoprostol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women who receive ergometrine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon, papal, misotac</intervention_name>
    <description>Using different drugs to prevent atonic PPH during CD in high risk group</description>
    <arm_group_label>Pregnant Women who receive carbetocin</arm_group_label>
    <arm_group_label>Pregnant women who receive ergometrine</arm_group_label>
    <arm_group_label>Pregnant women who receive misoprostol</arm_group_label>
    <arm_group_label>Pregnant women who receive oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Prevention of atonic PPH during CD in high risk group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant full term&gt;37 w 2. Maternal age 19- 40 3.physical state 1&amp;2 4.patient&#xD;
             willing to enter the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.who refuse to participate in study 2.immunocomprmized and patients who had&#xD;
             contraindicated from any of drugs used 3.patients with hypersensitivity to any drug&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Randa Wanees Ahmed</investigator_full_name>
    <investigator_title>Randa Wanees Ahmed</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

